VIA
SNOA icon

Vantage Investment Advisors’s Sonoma Pharmaceuticals SNOA Stock Holding History

Vantage Investment Advisors’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-3
Closed -$9K – 759
2014
Q2 		$9K Buy
+3
New +$8.88K 0.01% 486

Other funds holding SNOA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Vantage Investment Advisors's SNOA Position: Q3 2014 in Review

Vantage Investment Advisors sold out of Sonoma Pharmaceuticals (SNOA) in Q3 2014, closing a stake of 3 shares — an estimated $9K sold.

Vantage Investment Advisors first reported a position in SNOA in Q2 2014 and held it in 1 quarter. The position peaked at $9K in Q2 2014. 12 funds tracked by Wall St. Rank hold SNOA as of Q3 2014.

  • Vantage Investment Advisors reported no remaining Sonoma Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Vantage Investment Advisors sold 3 Sonoma Pharmaceuticals shares in Q3 2014, an estimated $9K.
  • Vantage Investment Advisors first reported a position in Sonoma Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Vantage Investment Advisors's Sonoma Pharmaceuticals position peaked at $9K in Q2 2014.
  • 12 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q3 2014.

Based on Vantage Investment Advisors's 13F filing for Q3 2014, filed 31 Oct 2014.